PT2906551T - Formas cristalinas de um inibidor de fator xia - Google Patents
Formas cristalinas de um inibidor de fator xiaInfo
- Publication number
- PT2906551T PT2906551T PT137802872T PT13780287T PT2906551T PT 2906551 T PT2906551 T PT 2906551T PT 137802872 T PT137802872 T PT 137802872T PT 13780287 T PT13780287 T PT 13780287T PT 2906551 T PT2906551 T PT 2906551T
- Authority
- PT
- Portugal
- Prior art keywords
- crystalline forms
- factor xia
- xia inhibitor
- inhibitor
- factor
- Prior art date
Links
- 229940122036 Factor XIa inhibitor Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261712850P | 2012-10-12 | 2012-10-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2906551T true PT2906551T (pt) | 2018-05-10 |
Family
ID=49474724
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT137802872T PT2906551T (pt) | 2012-10-12 | 2013-10-11 | Formas cristalinas de um inibidor de fator xia |
Country Status (34)
Country | Link |
---|---|
US (1) | US9920034B2 (pt) |
EP (1) | EP2906551B1 (pt) |
JP (1) | JP6154473B2 (pt) |
KR (1) | KR102143257B1 (pt) |
CN (1) | CN104837833B (pt) |
AU (1) | AU2013329125B2 (pt) |
BR (1) | BR112015007937A2 (pt) |
CA (1) | CA2888100A1 (pt) |
CL (1) | CL2015000916A1 (pt) |
CO (1) | CO7350621A2 (pt) |
CY (1) | CY1120238T1 (pt) |
DK (1) | DK2906551T3 (pt) |
EA (1) | EA032092B1 (pt) |
ES (1) | ES2668318T3 (pt) |
HK (1) | HK1212333A1 (pt) |
HR (1) | HRP20180465T1 (pt) |
HU (1) | HUE038272T2 (pt) |
IL (1) | IL238089B (pt) |
LT (1) | LT2906551T (pt) |
MA (1) | MA38071B1 (pt) |
MX (1) | MX351848B (pt) |
MY (1) | MY173058A (pt) |
NO (1) | NO2819265T3 (pt) |
NZ (1) | NZ707990A (pt) |
PE (1) | PE20150639A1 (pt) |
PH (1) | PH12015500678A1 (pt) |
PL (1) | PL2906551T3 (pt) |
PT (1) | PT2906551T (pt) |
RS (1) | RS57039B1 (pt) |
SG (1) | SG11201502605PA (pt) |
SI (1) | SI2906551T1 (pt) |
TR (1) | TR201807316T4 (pt) |
WO (1) | WO2014059203A1 (pt) |
ZA (1) | ZA201503238B (pt) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201319068A (zh) | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | 作為xia因子抑制劑之環狀p1接合劑 |
TW201311689A (zh) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | 作為因子xia抑制劑之新穎巨環化合物 |
AU2012322085B2 (en) | 2011-10-14 | 2017-05-04 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor Xia inhibitors |
US9315519B2 (en) | 2012-10-12 | 2016-04-19 | Bristol-Myers Squibb Company | Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors |
US9403774B2 (en) | 2012-10-12 | 2016-08-02 | Bristol-Myers Squibb Company | Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
EP2978751B1 (en) | 2013-03-25 | 2018-12-05 | Bristol-Myers Squibb Company | Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors |
NO2760821T3 (pt) | 2014-01-31 | 2018-03-10 | ||
JP6464176B2 (ja) | 2014-01-31 | 2019-02-06 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 芳香族p2’基を有する第xia因子阻害剤としてのマクロ環 |
ES2714283T3 (es) | 2014-09-04 | 2019-05-28 | Bristol Myers Squibb Co | Macrociclos de diamida que son inhibidores de FXIa |
US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
WO2016205482A1 (en) | 2015-06-19 | 2016-12-22 | Bristol-Myers Squibb Company | Diamide macrocycles as factor xia inhibitors |
EP3328852B1 (en) | 2015-07-29 | 2021-04-28 | Bristol-Myers Squibb Company | Factor xia macrocyclic inhibitors bearing a non-aromatic p2' group |
CN107849026B (zh) | 2015-07-29 | 2021-01-01 | 百时美施贵宝公司 | 携带烷基或环烷基p2′部分的因子xia大环抑制剂 |
CN106496249B (zh) * | 2015-09-07 | 2019-12-13 | 江苏恒瑞医药股份有限公司 | 噁唑并吲哚类衍生物、其制备方法及其在医药上的应用 |
EP3371162B1 (en) | 2015-10-29 | 2022-01-26 | Merck Sharp & Dohme Corp. | Macrocyclic spirocarbamate derivatives as factor xia inhibitors, pharmaceutically acceptable compositions and their use |
US10143681B2 (en) | 2016-08-22 | 2018-12-04 | Merck Sharp & Dohme Corp. | Factor XIa inhibitors |
CN109867660A (zh) * | 2017-12-01 | 2019-06-11 | 四川科伦博泰生物医药股份有限公司 | 含季铵离子的四氢异喹啉酰胺化合物及其药物用途 |
CN111655686B (zh) | 2018-03-28 | 2024-02-09 | 四川科伦博泰生物医药股份有限公司 | 四氢异喹啉类衍生物及其制备方法和用途 |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR7155E (fr) | 1906-03-16 | 1907-05-23 | Rene Gabriel Poncet | Séchoir rotatif |
FR1525186A (fr) | 1967-03-29 | 1968-05-17 | Roussel Uclaf | Nouvelles pénicillines et procédé de préparation |
ATA937274A (de) | 1973-12-17 | 1978-02-15 | Thomae Gmbh Dr K | Verfahren zur herstellung neuer araliphatischer ketone |
DE4034829A1 (de) | 1990-11-02 | 1992-05-07 | Merck Patent Gmbh | Cyclopeptide |
JP3190431B2 (ja) | 1991-07-01 | 2001-07-23 | 三菱化学株式会社 | ケトン誘導体 |
GB9206757D0 (en) | 1992-03-27 | 1992-05-13 | Ferring Bv | Novel peptide receptor ligands |
US5624936A (en) | 1995-03-29 | 1997-04-29 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
WO1996034010A2 (en) | 1995-03-29 | 1996-10-31 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
AU717298B2 (en) | 1996-04-03 | 2000-03-23 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5869682A (en) | 1996-04-03 | 1999-02-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
TW557297B (en) | 1997-09-26 | 2003-10-11 | Abbott Lab | Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same |
KR100928878B1 (ko) | 1998-03-19 | 2009-11-30 | 버텍스 파마슈티칼스 인코포레이티드 | 카스파제의 억제제 |
ES2310039T3 (es) | 1998-05-26 | 2008-12-16 | Warner-Lambert Company Llc | Pirimidinas biciclicas y 3,4-dihidropirimidinas biciclicas como inhibidores de la proliferacion celular. |
US6307049B1 (en) | 1998-09-30 | 2001-10-23 | The Procter & Gamble Co. | Heterocyclic 2-substituted ketoamides |
HUP0105437A3 (en) | 1999-01-02 | 2003-03-28 | Aventis Pharma Gmbh | Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them |
EP1016663A1 (en) | 1999-01-02 | 2000-07-05 | Aventis Pharma Deutschland GmbH | Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor Xa activity) |
SK14232001A3 (sk) | 1999-04-09 | 2002-06-04 | Basf Aktiengesellschaft | Nízkomolekulové inhibítory komplementárnych proteáz |
EP1125925A1 (en) | 2000-02-15 | 2001-08-22 | Applied Research Systems ARS Holding N.V. | Amine derivatives for the treatment of apoptosis |
CA2408486A1 (en) | 2000-05-11 | 2001-11-15 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline analogs useful as growth hormone secretagogues |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
AU2002322802A1 (en) | 2001-07-27 | 2003-02-17 | Merck And Co., Inc. | Thrombin inhibitors |
WO2003041641A2 (en) | 2001-11-09 | 2003-05-22 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity |
US7138412B2 (en) | 2003-03-11 | 2006-11-21 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives useful as serine protease inhibitors |
US7129264B2 (en) | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
AU2004263508A1 (en) | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
US7417063B2 (en) | 2004-04-13 | 2008-08-26 | Bristol-Myers Squibb Company | Bicyclic heterocycles useful as serine protease inhibitors |
US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
US20100190688A1 (en) | 2004-07-12 | 2010-07-29 | Bin Chao | Tetrapeptide analogs |
WO2006076575A2 (en) | 2005-01-13 | 2006-07-20 | Bristol-Myers Squibb Company | Substituted biaryl compounds as factor xia inhibitors |
US20060183771A1 (en) | 2005-02-17 | 2006-08-17 | Seiffert Dietmar A | Novel combination of selective factor VIIa and/or factor XIa inhibitors and selective plasma kallikrein inhibitors |
JP4955009B2 (ja) * | 2005-11-11 | 2012-06-20 | エフ.ホフマン−ラ ロシュ アーゲー | 凝固因子Xaの阻害剤としての炭素環式縮合環アミン |
JP2009519966A (ja) | 2005-12-14 | 2009-05-21 | ブリストル−マイヤーズ スクイブ カンパニー | セリンプロテアーゼ阻害剤として有用な6員ヘテロ環 |
US8466295B2 (en) | 2005-12-14 | 2013-06-18 | Bristol-Myers Squibb Company | Thiophene derivatives as factor XIa inhibitors |
ATE511502T1 (de) | 2005-12-14 | 2011-06-15 | Bristol Myers Squibb Co | Arylpropionamid-, arylacrylamid-, arylpropinamid- oder arylmethylharnstoffanaloge als faktor-xia- inhibitoren |
TW200745062A (en) | 2005-12-23 | 2007-12-16 | Bristol Myers Squibb Co | Macrocyclic factor VIIA inhibitors useful as anticoagulants |
WO2008076805A2 (en) | 2006-12-15 | 2008-06-26 | Bristol-Myers Squibb Company | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors |
PE20081775A1 (es) | 2006-12-20 | 2008-12-18 | Bristol Myers Squibb Co | Compuestos macrociclicos como inhibidores del factor viia |
CN101784516B (zh) | 2007-06-13 | 2014-07-02 | 百时美施贵宝公司 | 作为凝血因子抑制剂的二肽类似物 |
US8324199B2 (en) * | 2008-03-13 | 2012-12-04 | Bristol-Myers Squibb Company | Pyridazine derivatives as factor xia inhibitors |
WO2010151317A1 (en) | 2009-06-22 | 2010-12-29 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
WO2011002520A2 (en) | 2009-07-02 | 2011-01-06 | Angion Biomedica Corp. | Small molecule inhibitors of parp activity |
AR077695A1 (es) | 2009-08-04 | 2011-09-14 | Schering Corp | Derivados de pirimidina como inhibidores del factor ixa |
CA2789622C (en) | 2010-02-11 | 2018-04-03 | Bristol-Myers Squibb Company | Macrocycles as factor xia inhibitors |
WO2013009527A2 (en) | 2011-07-08 | 2013-01-17 | Merck Sharp & Dohme Corp. | Factor ixa inhibitors |
TW201311689A (zh) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | 作為因子xia抑制劑之新穎巨環化合物 |
TW201319068A (zh) | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | 作為xia因子抑制劑之環狀p1接合劑 |
EP2766345B1 (en) | 2011-10-14 | 2016-03-16 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
JP6033318B2 (ja) | 2011-10-14 | 2016-11-30 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 第XIa因子阻害剤としての置換テトラヒドロイソキノリン化合物 |
AU2012322085B2 (en) * | 2011-10-14 | 2017-05-04 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor Xia inhibitors |
NO2794597T3 (pt) | 2011-12-21 | 2018-04-14 | ||
WO2013111108A1 (en) | 2012-01-27 | 2013-08-01 | Novartis Ag | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
EP2807156A1 (en) | 2012-01-27 | 2014-12-03 | Novartis AG | Aminopyridine derivatives as plasma kallikrein inhibitors |
JP2015083542A (ja) | 2012-02-08 | 2015-04-30 | 大日本住友製薬株式会社 | 3位置換プロリン誘導体 |
AU2013258043B2 (en) | 2012-05-10 | 2017-11-30 | Bayer Pharma Aktiengesellschaft | Antibodies capable of binding to the coagulation factor XI and/or its activated form factor XIa and uses thereof |
GB201209138D0 (en) | 2012-05-24 | 2012-07-04 | Ono Pharmaceutical Co | Compounds |
TW201416362A (zh) | 2012-07-19 | 2014-05-01 | Dainippon Sumitomo Pharma Co | 1-(環烷基羰基)脯胺酸衍生物 |
JP6082463B2 (ja) | 2012-08-03 | 2017-02-15 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 第xia因子阻害剤としてのジヒドロピリドンp1 |
WO2014022766A1 (en) | 2012-08-03 | 2014-02-06 | Bristol-Myers Squibb Company | Dihydropyridone p1 as factor xia inhibitors |
US9403774B2 (en) | 2012-10-12 | 2016-08-02 | Bristol-Myers Squibb Company | Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
US9315519B2 (en) | 2012-10-12 | 2016-04-19 | Bristol-Myers Squibb Company | Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors |
US9708308B2 (en) | 2012-12-19 | 2017-07-18 | Merck Sharp Dohme Corp. | Factor IXa inhibitors |
GB201300304D0 (en) | 2013-01-08 | 2013-02-20 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
GB2510407A (en) | 2013-02-04 | 2014-08-06 | Kalvista Pharmaceuticals Ltd | Aqueous suspensions of kallikrein inhibitors for parenteral administration |
EP2978751B1 (en) | 2013-03-25 | 2018-12-05 | Bristol-Myers Squibb Company | Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors |
-
2013
- 2013-10-11 ES ES13780287.2T patent/ES2668318T3/es active Active
- 2013-10-11 SG SG11201502605PA patent/SG11201502605PA/en unknown
- 2013-10-11 EP EP13780287.2A patent/EP2906551B1/en active Active
- 2013-10-11 MY MYPI2015701150A patent/MY173058A/en unknown
- 2013-10-11 BR BR112015007937A patent/BR112015007937A2/pt not_active Application Discontinuation
- 2013-10-11 CN CN201380064797.5A patent/CN104837833B/zh active Active
- 2013-10-11 KR KR1020157011941A patent/KR102143257B1/ko active IP Right Grant
- 2013-10-11 DK DK13780287.2T patent/DK2906551T3/en active
- 2013-10-11 CA CA2888100A patent/CA2888100A1/en not_active Abandoned
- 2013-10-11 TR TR2018/07316T patent/TR201807316T4/tr unknown
- 2013-10-11 EA EA201590548A patent/EA032092B1/ru not_active IP Right Cessation
- 2013-10-11 PT PT137802872T patent/PT2906551T/pt unknown
- 2013-10-11 LT LTEP13780287.2T patent/LT2906551T/lt unknown
- 2013-10-11 WO PCT/US2013/064423 patent/WO2014059203A1/en active Application Filing
- 2013-10-11 MX MX2015004328A patent/MX351848B/es active IP Right Grant
- 2013-10-11 HU HUE13780287A patent/HUE038272T2/hu unknown
- 2013-10-11 RS RS20180328A patent/RS57039B1/sr unknown
- 2013-10-11 SI SI201330987T patent/SI2906551T1/en unknown
- 2013-10-11 JP JP2015536906A patent/JP6154473B2/ja active Active
- 2013-10-11 PL PL13780287T patent/PL2906551T3/pl unknown
- 2013-10-11 AU AU2013329125A patent/AU2013329125B2/en not_active Ceased
- 2013-10-11 NZ NZ707990A patent/NZ707990A/en not_active IP Right Cessation
- 2013-10-11 PE PE2015000477A patent/PE20150639A1/es not_active Application Discontinuation
- 2013-10-11 US US14/434,507 patent/US9920034B2/en active Active
-
2014
- 2014-05-21 NO NO14169333A patent/NO2819265T3/no unknown
-
2015
- 2015-03-26 PH PH12015500678A patent/PH12015500678A1/en unknown
- 2015-04-01 IL IL238089A patent/IL238089B/en active IP Right Grant
- 2015-04-10 CL CL2015000916A patent/CL2015000916A1/es unknown
- 2015-05-07 MA MA38071A patent/MA38071B1/fr unknown
- 2015-05-07 CO CO15104857A patent/CO7350621A2/es unknown
- 2015-05-11 ZA ZA2015/03238A patent/ZA201503238B/en unknown
-
2016
- 2016-01-07 HK HK16100130.3A patent/HK1212333A1/xx not_active IP Right Cessation
-
2018
- 2018-03-20 HR HRP20180465TT patent/HRP20180465T1/hr unknown
- 2018-05-18 CY CY20181100522T patent/CY1120238T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1212333A1 (en) | Crystalline forms of a factor xia inhibitor xia | |
HUS2200030I1 (hu) | Prolil hidroxiláz inhibitor kristályos alakjai | |
HRP20181751T1 (hr) | Kristalni oblici inhibitora prolil hidroksilaze | |
HRP20170784T8 (hr) | Supstituirani spojevi tetrahidroizohinolina kao inhbitori xia faktora | |
HK1211921A1 (en) | Inhibitor compounds | |
RS55581B1 (sr) | Dihidropiridon kao inhibitor faktora xia | |
HK1200454A1 (zh) | 琥珀酸鹽的晶形 | |
GB201211019D0 (en) | Inhibitor compounds | |
EP2900240A4 (en) | CRYSTALLINE FORM OF REVERSE TRANSCRIPTASE INHIBITOR |